Optimi Health Launches Standardized Psilocybin Microdose Capsules for Clinical Research
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
WASHINGTON, D.C., April 24, 2026 The U.S. Food and Drug Administration has announced a series of accelerated regulatory actions...
